Bristol Myers, Bluebird Bio Stocks Up As Blood Cancer Treatment Gets FDA Priority ReviewInvestors Business Daily • 09/22/20
U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)Business Wire • 09/22/20
Bristol-Myers Squibb Company (BMY) Management Presents at European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Transcript)Seeking Alpha • 09/22/20
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER TrialBusiness Wire • 09/19/20
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Two Cycles of Chemotherapy as First-Line Treatment of Metastatic Non-Small Cell Lung CancerBusiness Wire • 09/18/20
Bristol Myers Squibb to Announce Results for Third Quarter 2020 on November 5, 2020Business Wire • 09/17/20
Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr. Reddy’sBusiness Wire • 09/17/20
Bristol Myers Squibb (BMY) Stock Moves -0.13%: What You Should KnowZacks Investment Research • 09/16/20
Monoclonal Antibodies: A Good Place To Be In The Time Of Covid-19 And Stock Market BubblesSeeking Alpha • 09/15/20
Obsidian Therapeutics Announces Bristol Myers Squibb Opt-In of cytoDRiVE™ Cell Therapy CandidatePRNewsWire • 09/15/20
European Medicines Agency Validates Bristol Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for First-line Treatment of Malignant Pleural MesotheliomaBusiness Wire • 09/15/20
Daily Dividend Report: AbbVie, Bristol Myers Squibb, Colgate-Palmolive, American Tower, CernerForbes • 09/11/20
3 Incredibly Strong Stocks to Buy That Should Thrive Even If the Stock Market Crashes AgainThe Motley Fool • 09/11/20
Bristol Myers Squibb (BMY) Stock Moves -1.34%: What You Should KnowZacks Investment Research • 09/10/20